Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00195_DB00730_nanopub.RA2mF7VGH0WscYGNoNfBttR9ALY4L2GCvyn56ZkSoBUj0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00195_DB00730 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00195_DB00730 label "DDI between Betaxolol and Thiabendazole - The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Betaxolol by decreasing Betaxolol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Betaxolol if Thiabendazole is initiated, discontinued or dose changed [drugbank_resource:DB00195_DB00730]" assertion.
- drugbank_resource:DB00195_DB00730 identifier "drugbank_resource:DB00195_DB00730" assertion.
- drugbank_resource:DB00195_DB00730 title "DDI between Betaxolol and Thiabendazole - The strong CYP1A2 inhibitor, Thiabendazole, may increase the effects and toxicity of Betaxolol by decreasing Betaxolol metabolism and clearance. Monitor for changes in the therapeutic and adverse effects of Betaxolol if Thiabendazole is initiated, discontinued or dose changed" assertion.
- drugbank:DB00730 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00195_DB00730 assertion.
- drugbank:DB00195 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00195_DB00730 assertion.